GB002 (seralutinib)

DRUG2 trials

Sponsors

GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc., Gossamer Bio USA, Inc.

Conditions

Pulmonary Arterial HypertensionPulmonary Artery Hypertension

Phase 2

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

CompletedNCT04456998

GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.Pulmonary Artery Hypertension

Start: 2020-11-12End: 2022-11-01Updated: 2023-11-07

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Active, not recruitingNCT04816604

Gossamer Bio USA, Inc.Pulmonary Arterial Hypertension

Start: 2021-04-05End: 2027-12-01Updated: 2026-07-27

Related Papers

Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study

Advances in Therapy2025-08-111 citations

Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.

2024-05-0240 citations

Effects of inhaled seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)

European Heart Journal2023-11-01

Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): results of the TORREY phase 2 imaging substudy

2023-09-095 citations

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension

Pulmonary Circulation2021-10-0153 citations

Late Breaking Abstract - Evidence of target engagement and pathway modulation: biomarker analysis of the phase 1b inhaled seralutinib study

2021-09-05